In addition, ASCs/MSCs were also reported to increase the chemotherapy resistance of other cancer entities, including colorectal [211], ovarian [212,213,214], lung [215], squamous cell carcinoma [216], and acute myeloid leukemia [217], by modulating PDGF-BB [213], X-linked inhibitor of apoptosis (XIAP) [218], Notch [217], STAT3 [101], Hedgehog [214], and p53 signaling [211]. Here, XIAP is linked to acute myeloid leukemia.